Abstract
Background
Pneumonia is the leading cause of childhood mortality worldwide. The WHO recommends presumptive treatment based on clinical syndromes. Recent studies raise concerns over the frequency of treatment failure in Africa.
Methods
We applied a definition of treatment failure to data prospectively collected from children who were 2-59 months with severe, or very severe pneumonia admitted to Kilifi District Hospital, Kenya form May 2007 through May 2008 and treated using WHO guidelines. The primary outcome was treatment failure at 48 hours.
Results
Of 568 children, median age 11 months, 165 (29%) had very severe pneumonia, 30 (5.3%) a positive HIV test and 62 (11%) severe malnutrition. 111 (20%, 95% CI 17-23%) children failed treatment at 48 hours and 34 (6.0%) died, 22 (65%) deaths occurred before 48 hours. Of 353 children with severe pneumonia, without HIV or severe malnutrition, 42 (12%) failed to respond at 48 hours, 15 (4.3%) failed at 5 days and one child (0.3%) died. Among 215 children with either severe pneumonia complicated by HIV or severe malnutrition, or very severe pneumonia, 69 (32%) failed to treatment at 48 hours, 47 (22%) failed at 5 days and 33 (16%) died. Treatment failure at 48 hours was associated with shock, bacteremia, very severe pneumonia, Sa02<95%, severe malnutrition, HIV, and age <1 year in multivariable models.
Conclusions
In this setting, few children with uncomplicated severe pneumonia fail treatment or die under current guidelines. Deaths mainly occurred early and may be reduced by improving prevention, pre-hospital care and treatment of sepsis.
Keywords: Pneumonia, Treatment Failure, Kenya
INTRODUCTION
Acute lower respiratory tract infection is the leading cause of childhood mortality worldwide, mostly due to pneumonia, and mostly in developing countries.(1-3) The WHO recommends presumptive antibiotic treatment based on clinical syndromes involving history of cough or difficulty breathing with lower chest wall indrawing, or signs indicating very severe pneumonia.(4) These guidelines were developed before the HIV pandemic, before conjugate vaccines and in a context of different antimicrobial sensitivities. Recent reports from Southern Africa where there is a high prevalence of HIV infection, suggest that treatment failure is frequent. (5, 6) There are no recent data on the outcomes of pneumonia treatment from areas of Africa with a lower HIV prevalence.
WHO guidelines recommend reviewing treatment after 48 hours and changing antibiotics if there is no improvement, i.e. “slower breathing, less fever, eating better”.(7) The guidelines are unclear if one or all of the criteria must be met, and what quantity or quality of improvement is required to be “improved”. Labeling a child as failing when they are responding (albeit perhaps more slowly) may result in unnecessary changes of antibiotics or expensive investigations. However, not recognizing treatment failure may lead to a poor outcome when a change in antimicrobials or other procedures may have been beneficial.
In the face of these existing data and theoretical concerns, empiric data on the frequency of treatment failure in different regions of Africa are essential. We aimed to determine the frequency of treatment failure among children meeting clinical criteria for severe, and very severe pneumonia, admitted to a rural Kenyan district hospital and treated according to standard guidelines.
METHODS
Location
Kilifi District Hospital is located in a rural area in coastal Kenya. The hospital serves a predominantly rural farming population of ~240,000 of whom 18% are under 5 years old. Haemophilus influenzae type b conjugate vaccine, given at 6, 10, and 14 weeks, was introduced in late 2001, with high coverage and 90% reduction in disease due to Hib.(8) Pneumococcal conjugate vaccine was not introduced at the time of this study. The HIV prevalence at the hospital antenatal clinic was approximately 5% in 2007.
Patients and clinical methods
We applied an a priori definition of treatment failure to data prospectively collected at admission and daily thereafter among children aged 2 to 59 months meeting the WHO syndromic definition of “severe pneumonia” or “very severe pneumonia” (7) at admission between 26th May 2007 and 25th May 2008. Part of this cohort was previously described in relation to the viral etiology of severe pneumonia.(9) RSV was the most frequently detected respiratory virus, and the only virus significantly more frequently detected amongst children with severe pneumonia than amongst healthy controls or children with symptoms of mild upper respiratory tract infection. (9)
Severe pneumonia was defined as a history of cough or difficulty breathing and lower chest wall indrawing. The presence of inability to drink, central cyanosis or reduced level of consciousness defined very severe pneumonia.(7) As oxygen saturation monitoring was available, a modification of the WHO criteria, peripheral oxygen saturation <90% (Nelcor, USA) was used in addition to central cyanosis to define very severe pneumonia. Severe malnutrition was defined as weight for height <-3 z scores by WHO reference standards, or the presence of kwashiorkor. HIV testing was performed according to national policy for all pediatric hospital admissions using rapid antibody tests. Parents or guardians of those testing positive were given further counseling and referred for comprehensive care. Severe anemia was defined as hemoglobin <5 g/dl. Reduced conscious level was defined as prostration or coma (Blantyre coma score <3). Signs of shock were defined as weak pulse, capillary refill time >2 seconds or palpable core-limb temperature gradient.
A blood culture and malaria slide was taken at admission for all children. A nasal wash specimen for viral detection by multiplex PCR was taken in children without severe cardio-respiratory compromise. Microbiologic and virologic methods have been previously described.(9)
Clinical care was provided by research medical officers and clinical officers trained in the recognition of clinical signs and treatment of pneumonia according to WHO guidelines, including antibiotic treatment as follows: intravenous benzylpenicillin to children with severe pneumonia; either chloramphenicol alone or ampicillin plus gentamicin for children with very severe pneumonia; ; intravenous ampicillin for children with severe malnutrition; and intravenous ampicillin plus gentamicin plus cotrimoxazole at therapeutic doses for children with a positive HIV antibody test.(7, 10) Oxygen was administered if SaO2<90%. The most severely ill children were managed on a high dependency unit, but mechanical ventilation was not available. Malaria parasitemia was treated according to national guidelines. Daily clinical observations were recorded by research clinicians and trained ward assistants. Treatment was changed by clinicians applying the WHO guidelines and reviewing laboratory results rather than by applying the study definition of failure. Because of processing time, results of admission blood cultures including antimicrobial sensitivities and viral diagnoses were not usually available within 48 hours.
The study was approved by the Kenya Medical Research Institute/National Ethical Review Committee. Written informed consent was obtained from the parent or guardian of each child.
Definition of treatment failure
The two elements in defining treatment failure are the length of time before re-assessment, and the criteria for failure.(5, 11-16) We searched PubMed (1955–2010) for studies defining treatment failure in severe pneumonia using the search term (pneumonia or “lower respiratory tract infection”) and (children) and (failure or guideline*). The search was limited to human studies, 1699 abstracts were reviewed and full-text articles were evaluated if the abstract suggested potential relevance. Further articles were identified through searching the reference lists of the selected articles. Findings are summarized in table 1. Our definition of treatment failure was established before data analysis was performed.
TABLE 1.
Reference | Study population | N | Clinical Definition of Treatment Failure | Failure |
---|---|---|---|---|
Shann et al. 1985(29) |
Ages not stated; Papua New Guinea; Inpatients; Severe pneumonia | 748 | At any point: Change of antibiotic treatment; Death | 15.9% |
Strauss et al. 1998(30) |
2–59 months; Pakistan; Outpatient and inpatient; Non-severe and severe pneumonia | 595 | At 48 hours, any of: Resting SaO2 ≤ 87%; tachypnoea; any danger sign; No improvement or deterioration in the opinion of a senior clinician | 20.5% |
Duke et al. 2002(31) |
1-59 months; Papua New Guinea; Inpatient; Very severe pneumonia | 1116 | At 5 days, any 4 of: Fever, Tachypnoea/apnoeas, chest wall indrawing, crepitations, bronchial breathing, low oxygen sats; Death ; Readmission within 1 month | 18.6% |
Addo-Yobo et al. 2004(14) |
3–59 month; International; Inpatient; Severe pneumonia | 1702 | At 48 hours, any 1 of: Danger signs, low SaO2, persistent indrawing, serious adverse drug reaction, new antibiotic, new comorbidity, abscondment, death | 19% |
McNally et al. 2007(5) |
1-59 months; South Africa; Inpatient; Severe and very severe pneumonia | 358 | At 48 hours, persistence or worsening of any 1 of: heart rate, respiratory rate, temperature, inability to drink, increased oxygen requirements; New danger signs; Absconded; Change of antibiotic for new disease or blood culture result; Death | 35% |
Asghar et al. 2008 (12) (SPEAR study) |
2-59 months; International; Inpatient; Very severe pneumonia | 958 | At day 5, persistent or new: Inability to drink, tachypnoea, reduced conscious level, meningitis, empyema, renal failure, septic shock; Serious adverse drug reaction; Change of antibiotic treatment; Abscondment; Death | 13.5% |
Hazir et al 2008(15) |
3-59 months; Inpatient versus outpatient; Severe pneumonia | 2037 | At day 3: Clinical deterioration; Persistence of fever with lower chest indrawing; Hospitalisation of outpatient; Development of comorbid condition requiring antibiotic; Abscondment; Death | 8% |
Addo Yobo et al. 2011(32) |
2-59 months, multi-national; Severe pneumonia | 823 | At 72 hours, persistence of fever and lower chest indrawing. Or, at day 6, clinical deterioration; Inability to take oral medication because of persisting vomiting; serious adverse event related to amoxicillin; developing a co-morbid condition; either fever or lower chest indrawing; new chest indrawing or fast breathing | 9.2% |
We defined treatment failure at 48 hours as i) worsening, compared to admission findings, of one or more of these clinical abnormalities: conscious level, SaO2 <90%; respiratory rate (must have increased by at least 5 breaths/min), or temperature (if initially <37.5°C, must have increased to >37.5°C); or ii) or no improvement in any these clinical abnormalities; or iii) a new finding of: empyema, bacterial meningitis, signs of shock or renal impairment (creatinine >100 mmol/L); or iv) death.
We defined treatment failure at 5 days as i) meeting the 48 hour failure criteria at day 5; or ii) persistence of any two of the clinical abnormalities used to define failure at 48 hours; or iii) persistence of lower chest wall indrawing; or iv) death.
Clinical criteria for treatment failure were applied independently at 48 hours and day 5. Because of concerns that evaluation at 48 hours may over-classify failure among children who are improving, and because the failure criteria for this analysis were not those used to adjust treatment at 48 hours, the definition was not cumulative. Thus, children failing at 48 hours did not fail at 5 days if they had improved by then. Death at any point before criteria were applied constituted treatment failure. Discharge was deemed non-failure.
Statistical analysis
The primary endpoint was overall treatment failure at 48 hours, with 95% confidence intervals. Because treatment guidelines differ for severe pneumonia, and very severe pneumonia, severe malnutrition and HIV, these groups were initially analyzed separately. Ages were not normally distributed and were compared using the Kruskall-Wallis test. Clinical features at admission among children who failed and did not fail were analyzed as odds ratios. Observations at 48 hours were assessed for association with failure at day 5, but no other serial measurements were analyzed. Finally, independent associations with failure at 48 hours, 5 days, and death before 48 hours were modeled by forward stepwise multivariable logistic regression, starting with variables with a univariate association (P<0.1). Variables were retained in the final models if the likelihood ratio test P value was <0.05. Because of differing treatment recommendations, severity (severe pneumonia or very severe pneumonia), HIV status, severe malnutrition and a variable for their interaction were also retained. Analyses were performed using STATA version 9 (StataCorp, College Station, TX, USA).
RESULTS
During the study period, 710 children were eligible. In 66, parents did not consent and 76 were excluded because one or more of the data items at admission, 48 hours or at 5 days were missing. Compared with the included children, the 142 excluded children did not differ in age: median 13 months (IQR 5.0 to 23 months, P=0.48), very severe pneumonia (n=39 (27%, P=0.71)), HIV status (n=7 (4.9%, P=0.87)), severe malnutrition (n=6 (4.2%, P=0.42)) or case fatality (n=7, (4.9%, P=0.63)). There were no significant differences in these characteristics between those who had refused consent and those with missing data.
Analysis included 568 (80%) children (57% male), median age 11 months (IQR 5.7 to 23 months), 165 (29%) of whom had very severe pneumonia. The median duration of cough prior to admission was 3 days, 134 (24%) had cough for ≥5 days and 21 (4.1%) for ≥14 days. A positive HIV antibody test was found in 30 (5.3%) children and 62 (11%) were severely malnourished.
Thirty four (6.0%) children died during hospital admission: 22 (65%) died before 48 hours, including 6 (18%) children admitted in extremis who died before antibiotics could be administered. Three children (9%) died between 48 hours and 5 days, and 9 (26%) died after 5 days.
Thirty two (5.6%) children were bacteremic at admission: 18/403 (4.5%) with severe pneumonia and 14/165 (8.5%) with very severe pneumonia (P=0.01). In a multivariable model including very severe pneumonia, HIV, severe malnutrition and age, only HIV was significantly associated with bacteremia: OR 7.89 (95% CI 3.11 to 20.0). The pathogens isolated were Streptococcus pneumoniae (15), E. coli (5), Staphylococcus aureus (3) beta hemolytic Streptococcus (3), non-Typhi Salmonella sp. (2), Haemophilus influenzae type b (1), Acinetobacter sp. (1), Serratia sp. (1), Burkholeria cepacia (1) and an unidentified, non-fermenting Gram negative rod (1).
A nasal wash sample for respiratory virus detection was taken in 480 children. A respiratory virus was detected in 192/350 (55%) admissions with severe pneumonia and 58/130 (45%) with very severe pneumonia. RSV was detected in 136 (28%) admissions: 105 (30%) in severe pneumonia and 31 (24%) in very severe pneumonia. Malaria parasitemia was present in 26 (4.7%) admissions.
At 48 hours, 111/568 (20%, 95% CI 17-23%) children had failed to respond. The risks of failure or death by 48 hours and 5 days are illustrated in table 2. We then compared the group of children with severe pneumonia that was uncomplicated by HIV or severe malnutrition to all other children (who had either severe pneumonia complicated by HIV or severe malnutrition, or very severe pneumonia). In these two groups, failure at 48 hours was observed in 42/353 (12%) and 69/215 (32%) respectively (P<0.001); failure at 5 days was observed in 15/353 (4.3%) and 47/215 (22%) respectively (P<0.001); and death occurred in 1/353 (0.3%) and 33/215 (16%) respectively (P<0.001).
TABLE 2.
Failure status at 48 hours | Failure status at day 5 | ||||
Pneumonia type |
Uncomplicat ed |
Complicat ed by HIV or malnutritio n |
Pneumonia type |
Uncomplicat ed |
Complicat ed by HIV or malnutritio n |
Severe | 42/353 (12%) |
14/50 (28%) P=0.002a |
Severe | 15/353 (4.2%) |
5/50 (10%) P=0.09a |
V. Severe | 39/131 (30%) P<0.001b |
16/34 (47%) P=0.06a P=0.07b |
V. Severe | 27/131 (21%) P<0.001b |
15/34 (44%) P<0.001a P=0.006b |
Cumulative deaths by 48
hours |
Cumulative deaths by day 5 | ||||
Pneumonia type |
Uncomplicat ed |
Complicat ed by HIV or malnutritio n |
Pneumonia type |
Uncomplicat ed |
Complicat ed by HIV or malnutritio n |
Severe | 0/353 (0%) | 1/50 (2%) P=0.12a |
Severe | 1/353 (0.3%) | 1/50 (2%) P=0.23a |
V. Severe | 15/131 (11%) P<0.001b |
6/34 (18%) P=0.39a P=1.0b |
V. Severe | 15/131 (11%) P<0.001b |
8/34 (24%) P=0.07a P=0.003b |
Complicated by HIV or severe malnutrition compared to uncomplicated
Very severe pneumonia compared to severe pneumonia
Amongst children with very severe pneumonia categorized on the basis of an oxygen saturation <90% alone, treatment failure at 48 hours (24/94 (26%)) occurred less frequently than amongst those categorized as very severe because of inability to drink or breastfeed, impaired consciousness or central cyanosis (31/71 (44%, P=0.014)), but more frequently than amongst children with severe pneumonia (56/403 (14%, P=0.006)).
The most common criteria for failure at 48 hours were: worsening respiratory rate, worsening temperature, worsening oxygen saturation or death (table 3). The most common criteria for failure at 5 days were persistent lower chest wall indrawing, persistent or worsening oxygen saturation or temperature, or death.
TABLE 3.
Criterion for treatment failure at 48 hours |
Frequency at 48 hours N=111 |
Frequency at 5 days N=62 |
---|---|---|
Worsening conscious level | 4 (3.6%) | 3 (5%) |
Persistent reduced conscious level | - | 0 (0%) |
Worsening SaO2 | 19 (17%) | 2 (3%) |
Persistent SaO2 <90% | - | 19 (31%) |
Worsening respiratory rate | 61 (55%) | 12 (19%) |
Persistent respiratory rate | - | 5 (8%) |
Worsening temperature | 22 (20%) | 1 (2%) |
Persistent temperature | - | 4 (6%) |
Persistent lower chest wall indrawing | - | 31 (50%) |
New empyema | 0 (0%) | 0 (0%) |
New bacterial meningitis | 2 (1.8%) | 2 (3%) |
New renal impairment | 0 (0%) | 1 (2%) |
New signs of shock | 3 (2.7%) | 4 (6%) |
Death | 22 (20%) | 25 (40%) |
Note: proportions exceed 100% as children may have had more than one reason for failure, there is no overlap with ‘death’.
The clinical features independently associated with failure at 48 hours and 5 days and death before 48 hours are shown in table 4. Variables that were examined, but not independently associated with treatment failure or death before 48 hours in the multivariable models were: gender, respiratory rate, temperature, severe anemia, malaria parasitemia and detection of a respiratory virus. For severe pneumonia, failure at 48 hours occurred in 19/105 (18%) of those with RSV detected, 31/192 (16%) with any other respiratory virus detected, 21/158 (13%) with no virus detected and 4/53 (8%) among untested children (P=0.34). For very severe pneumonia, failure at 48 hours occurred in 11/31 (35%) of those with RSV detected, 6/27 (22%) with any other respiratory virus detected, 17/72 (24%) with no virus detected and 21/35 (60%) among untested children (mostly untested because of respiratory or cardiovascular compromise) (P=0.25).
TABLE 4.
Exposure variable ascertained on admission |
Number exposed (%) N=568 |
Treatment failure at 48 hours |
Death before 48 hours |
Treatment failure at day 5 |
---|---|---|---|---|
Age < 1 year | 293 (52%) | 1.66 (1.05 – 2.61) |
- | - |
Very severe pneumonia | 165 (29%) | 1.93 (1.15 – 3.23) |
26.5 (3.36 – 208) |
2.93 (1.48 – 5.81) |
Oxygen saturation <95% at
admission |
134 (24%) | 1.78 (1.06 - 3.00) |
- | 2.88 (1.48 – 5.59) |
Signs of shock on admission | 43 (8%) | 2.52 (1.24 – 5.12) |
9.99 (3.36 – 29.7) |
2.66 (1.15 – 6.14) |
Bacteremia on admission | 32 (6%) | 3.06 (1.35 – 6.92) |
- | 4.91 (1.90 – 12.7) |
History of convulsions | 32 (6%) | - | 6.83 (2.01 – 23.2) |
- |
Cough for >14 days | 56 (10%) | - | - | 3.87 (1.83 – 8.19) |
Wheeze on admission | 89 (16%) | - | N/A * | - |
Positive HIV antibody test,
not severely malnourished Severe Malnutrition, negative HIV test Positive HIV test and severe malnutrition |
22 (4%) 54 (10%) 8 (2%) |
3.45 (1.31 – 9.06) 1.94 (1.01 – 3.74) 0.17 (0.02 – 1.48) |
4.62 (0.75 – 28.5) 1.37 (0.35 – 5.31) N/A ** |
2.21 (0.61 – 8.03) 1.80 (0.91 – 4.69) 0.46 (0.04 – 5.79) |
‘-‘ indicates that the factor did not contribute to that model.
No child with wheeze died within 48 hours.
No child with both HIV and malnutrition died within 48 hours.
For each exposure variable, the reference value is the absence of that exposure. For very severe pneumonia, the reference category is severe pneumonia. For HIV and severe malnutrition the reference category is having neither severe malnutrition nor a positive HIV test.
Among children who survived to 48 hours (n=546), their subsequent clinical progress was influenced very strongly by their existing response to treatment; by 5 days of admission, treatment failure was observed in 31% (28/89) of those who had already failed at 48 hours and in 2.6% (12/457) of those who had responded at 48 hours: OR 17.0 (95% CI 7.83 to 38.4). Restricting the analysis of clinical features at admission associated with failure at day 5 to those who had not failed at 48 hours, only one variable remained significantly associated: cough for >14 days: OR 10.9 (95% CI 2.87 to 41.5).
DISCUSSION
At 48 hours after admission, 20% of children at a rural Kenyan district hospital with severe or very severe pneumonia were failing to respond to treatment. Among children with severe pneumonia, uncomplicated by HIV or severe malnutrition, few children ultimately failed treatment or died (table 2). However, amongst children with very severe pneumonia, or the complications of HIV or severe malnutrition, one third failed to respond at 48 hours and one in six died. The majority of deaths occurred before 48 hours, principally amongst those who were profoundly ill at admission. Failure to respond by 48 hours was strongly associated with failure at 5 days.
Compared with the cohort studied by McNally et al in South Africa,(5) our participants were older, had a much lower prevalence of HIV infection or exposure (5.6% vs. 68%) and less very severe pneumonia (29% vs. 71%). Whilst we found that the overall risk of failure at 48 hours was lower than reported by McNally et al, amongst children with very severe pneumonia, HIV or severe malnutrition our finding that 32% had failed at 48 hours was comparable to the 35% reported in that study. Another cohort in South Africa and Zambia comparing children without HIV to those with mild or asymptomatic HIV infection was reported by Jeena et al.(6) In that study, which excluded severe malnutrition, the prevalence of HIV infection (23% confirmed) was much higher than in our cohort, and the overall proportion failing treatment at 2 days (12%) was similar to that which we found for uncomplicated severe pneumonia.
Our findings suggest that guidelines for treating very severe pneumonia and severe pneumonia complicated by HIV or severe malnutrition need to be re-examined. We did not aim to determine the full spectrum of etiology and there were too few bacterial isolates to analyze treatment failure in relation to in vitro antimicrobial susceptibilities. We did find that clinically identified sepsis or bacteremia at admission was strongly associated with death and treatment failure. Studies in Mozambique and Uganda, (17), (18) report a similar set of clinical parameters to be associated with fatal pneumonia: very severe pneumonia, HIV, severe malnutrition, hypoxemia and bacteremia.
The fact that deaths mainly occurred early suggests several potential strategies for reducing mortality: prevention through vaccination; early effective treatment in the community; earlier referral of hospitalized cases and improved supportive management of sepsis. The introduction of pneumococcal conjugate vaccination (PCV) is likely to significantly alter the etiology of childhood pneumonia. (19) Changes in outcomes following its introduction in Kenya in early 2011 will be analyzed using the same definitions of treatment failure. Strategies to improve care-seeking, access to care and referral are needed, (20, 21) and there is evidence that these can be successful.(22, 23) Treatment of lower risk ‘ambulatory’ cases of severe pneumonia as an outpatient with oral antibiotics may allow attention to be focused on more severely ill children.(14) The initial case management of suspected sepsis should include prompt administration of antibiotics since delays have been shown to be associated with poorer outcomes.(24, 25) However, the optimal fluid management of shock is controversial, with results of a large African trial that included children with pneumonia conflicting with existing guidelines such as the WHO Emergency Triage and Treatment (ETAT) recommendations. (26)
Children who were classified as having very severe pneumonia on the basis of pulse oximetry without impaired consciousness, inability to drink or central cyanosis failed treatment more frequently than those classified as having severe pneumonia. Furthermore, children admitted with mild hypoxemia (90 to 95%) did worse than those with higher oxygen saturations. Taken together, these findings strongly support the value of pulse oximetry in categorizing pneumonia severity. Previous studies of hypoxemia in childhood pneumonia have taken 90% oxygen saturation as the lower limit of normal at sea level. (27, 28) Randomized trials are needed on whether the threshold for providing oxygen should be raised.
Our study had several limitations. Data from a significant proportion of eligible admissions were not analyzed because one or more of the admission or daily observation variables were missing (11%), or consent was declined (9%). However, we identified no differences in clinical characteristics or case fatality between those excluded and those analyzed. Our data are also limited by being from only one site.
Acknowledgements
We thank the District Medical Officer of Health, the Director of the Centre, and the staff of Kilifi District Hospital for their support. We are grateful to all the Kenya Medical Research Institute (KEMRI)/Wellcome Trust clinical, laboratory, and computing staff for assistance with collecting the data. This article is published with the permission of the director of the Kenya Medical Research Institute.
Funding for the study was from The Wellcome Trust (UK), grant number 081186 (DJN, JAGS & JAB).
Footnotes
Conflicts of Interest and Source of Funding All authors declare no conflict of interest.
References
- 1.Bryce J, Boschi-Pinto C, Shibuya K, Black RE. WHO estimates of the causes of death in children. Lancet. 2005 Mar 26 1;Apr 26 1;365(9465):1147–52. doi: 10.1016/S0140-6736(05)71877-8. [DOI] [PubMed] [Google Scholar]
- 2.Rudan I, Boschi-Pinto C, Biloglav Z, Mulholland K, Campbell H. Epidemiology and etiology of childhood pneumonia. Bull World Health Organ. 2008 Aug 1;86(5):408–16. doi: 10.2471/BLT.07.048769. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Black RE, Cousens S, Johnson HL, Lawn JE, Rudan I, Bassani DG, Jha P, Campbell H, Walker CF, Cibulskis R, Eisele T, Liu L, Mathers C. Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet. 2010 Jun 5;375(9730):1969–87. doi: 10.1016/S0140-6736(10)60549-1. [DOI] [PubMed] [Google Scholar]
- 4.WHO . A manual for Doctors and other senior health workers. WHO; Geneva: 1990. Acute respiratory infections in children: Case management in small hospitals in developing countries. [Google Scholar]
- 5.McNally LM, Jeena PM, Gajee K, Thula SA, Sturm AW, Cassol S, Tomkins AM, Coovadia HM, Goldblatt D. Effect of age, polymicrobial disease, and maternal HIV status on treatment response and cause of severe pneumonia in South African children: a prospective descriptive study. Lancet. 2007 Apr 28;369(9571):1440–51. doi: 10.1016/S0140-6736(07)60670-9. [DOI] [PubMed] [Google Scholar]
- 6.Jeena P, Thea DM, MacLeod WB, Chisaka N, Fox MP, Coovadia HM, Qazi S. Failure of standard antimicrobial therapy in children aged 3-59 months with mild or asymptomatic HIV infection and severe pneumonia. Bull World Health Organ. 2006 Apr;84(4):269–75. doi: 10.2471/blt.04.015222. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.World Health Organization . Pocket book of hospital care for children : guidelines for the management of common illnesses with limited resources. World Health Organization; Geneva: 2005. Dept. of Child and Adolescent Health and Development. [Google Scholar]
- 8.Cowgill KD, Ndiritu M, Nyiro J, Slack MP, Chiphatsi S, Ismail A, Kamau T, Mwangi I, English M, Newton CR, Feikin DR, Scott JA. Effectiveness of Haemophilus influenzae type b Conjugate vaccine introduction into routine childhood immunization in Kenya. JAMA. 2006 Aug 9;296(6):671–8. doi: 10.1001/jama.296.6.671. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Berkley JA, Munywoki P, Ngama M, Kazungu S, Abwao J, Bett A, Lassauniere R, Kresfelder T, Cane PA, Venter M, Scott JA, Nokes DJ. Viral etiology of severe pneumonia among Kenyan infants and children. JAMA. 2010 May 26;303(20):2051–7. doi: 10.1001/jama.2010.675. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Report of a consultative meeting. World Health Organisation; Harare, Zimbabwe. Geneva: 2003. Management of Children with Pneumonia and HIV in low-resource settings. [Google Scholar]
- 11.Hazir T, Qazi SA, Bin Nisar Y, Maqbool S, Asghar R, Iqbal I, Khalid S, Randhawa S, Aslam S, Riaz S, Abbasi S. Comparison of standard versus double dose of amoxicillin in the treatment of non-severe pneumonia in children aged 2-59 months: a multi-centre, double blind, randomised controlled trial in Pakistan. Arch Dis Child. 2007 Apr;92(4):291–7. doi: 10.1136/adc.2005.092494. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Asghar R, Banajeh S, Egas J, Hibberd P, Iqbal I, Katep-Bwalya M, Kundi Z, Law P, MacLeod W, Maulen-Radovan I, Mino G, Saha S, Sempertegui F, Simon J, Santosham M, Singhi S, Thea DM, Qazi S. Chloramphenicol versus ampicillin plus gentamicin for community acquired very severe pneumonia among children aged 2-59 months in low resource settings: multicentre randomised controlled trial (SPEAR study) BMJ. 2008 Jan 12;336(7635):80–4. doi: 10.1136/bmj.39421.435949.BE. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Ayieko P, English M. Case management of childhood pneumonia in developing countries. Pediatr Infect Dis J. 2007 May;26(5):432–40. doi: 10.1097/01.inf.0000260107.79355.7d. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Addo-Yobo E, Chisaka N, Hassan M, Hibberd P, Lozano JM, Jeena P, MacLeod WB, Maulen I, Patel A, Qazi S, Thea DM, Nguyen NT. Oral amoxicillin versus injectable penicillin for severe pneumonia in children aged 3 to 59 months: a randomised multicentre equivalency study. Lancet. 2004 Sep 25 1;Oct 25 1;364(9440):1141–8. doi: 10.1016/S0140-6736(04)17100-6. [DOI] [PubMed] [Google Scholar]
- 15.Hazir T, Fox LM, Nisar YB, Fox MP, Ashraf YP, MacLeod WB, Ramzan A, Maqbool S, Masood T, Hussain W, Murtaza A, Khawar N, Tariq P, Asghar R, Simon JL, Thea DM, Qazi SA. Ambulatory short-course high-dose oral amoxicillin for treatment of severe pneumonia in children: a randomised equivalency trial. Lancet. 2008 Jan 5;371(9606):49–56. doi: 10.1016/S0140-6736(08)60071-9. [DOI] [PubMed] [Google Scholar]
- 16.Rasmussen ZA, Bari A, Qazi S, Rehman G, Azam I, Khan S, Aziz F, Rafi S, Roghani MT, Iqbal I, Nagi AG, Hussain W, Bano N, van Latum LJ, Khan M. Randomized controlled trial of standard versus double dose cotrimoxazole for childhood pneumonia in Pakistan. Bull World Health Organ. 2005 Jan;83(1):10–9. [PMC free article] [PubMed] [Google Scholar]
- 17.Sigauque B, Roca A, Bassat Q, Morais L, Quinto L, Berenguera A, Machevo S, Bardaji A, Corachan M, Ribo J, Menendez C, Schuchat A, Flannery B, Soriano-Gabarro M, Alonso PL. Severe pneumonia in Mozambican young children: clinical and radiological characteristics and risk factors. J Trop Pediatr. 2009 Dec;55(6):379–87. doi: 10.1093/tropej/fmp030. [DOI] [PubMed] [Google Scholar]
- 18.Nantanda R, Hildenwall H, Peterson S, Kaddu-Mulindwa D, Kalyesubula I, Tumwine JK. Bacterial aetiology and outcome in children with severe pneumonia in Uganda. Ann Trop Paediatr. 2008 Dec;28(4):253–60. doi: 10.1179/146532808X375404. [DOI] [PubMed] [Google Scholar]
- 19.Scott JA, English M. What are the implications for childhood pneumonia of successfully introducing Hib and pneumococcal vaccines in developing countries? PLoS Med. 2008 Apr 22;5(4):e86. doi: 10.1371/journal.pmed.0050086. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Hildenwall H, Nantanda R, Tumwine JK, Petzold M, Pariyo G, Tomson G, Peterson S. Care-seeking in the development of severe community acquired pneumonia in Ugandan children. Ann Trop Paediatr. 2009 Dec;29(4):281–9. doi: 10.1179/027249309X12547917869005. [DOI] [PubMed] [Google Scholar]
- 21.Kallander K, Hildenwall H, Waiswa P, Galiwango E, Peterson S, Pariyo G. Delayed care seeking for fatal pneumonia in children aged under five years in Uganda: a case-series study. Bull World Health Organ. 2008 May;86(5):332–8. doi: 10.2471/BLT.07.049353. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Theodoratou E, Al-Jilaihawi S, Woodward F, Ferguson J, Jhass A, Balliet M, Kolcic I, Sadruddin S, Duke T, Rudan I, Campbell H. The effect of case management on childhood pneumonia mortality in developing countries. Int J Epidemiol. 2010 Apr;39(Suppl 1):i155–71. doi: 10.1093/ije/dyq032. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Yeboah-Antwi K, Pilingana P, Macleod WB, Semrau K, Siazeele K, Kalesha P, Hamainza B, Seidenberg P, Mazimba A, Sabin L, Kamholz K, Thea DM, Hamer DH. Community case management of fever due to malaria and pneumonia in children under five in Zambia: a cluster randomized controlled trial. PLoS Med. 2010 Sep;7(9):e1000340. doi: 10.1371/journal.pmed.1000340. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Sandora TJ, Desai R, Miko BA, Harper MB. Assessing quality indicators for pediatric community-acquired pneumonia. Am J Med Qual. 2009 Sep-Oct;24(5):419–27. doi: 10.1177/1062860609337900. [DOI] [PubMed] [Google Scholar]
- 25.Muszynski JA, Knatz NL, Sargel CL, Fernandez SA, Marquardt DJ, Hall MW. Timing of correct parenteral antibiotic initiation and outcomes from severe bacterial community-acquired pneumonia in children. Pediatr Infect Dis J. 2011 Apr;30(4):295–301. doi: 10.1097/INF.0b013e3181ff64ec. [DOI] [PubMed] [Google Scholar]
- 26.Maitland K, Kiguli S, Opoka RO, Engoru C, Olupot-Olupot P, Akech SO, Nyeko R, Mtove G, Reyburn H, Lang T, Brent B, Evans JA, Tibenderana JK, Crawley J, Russell EC, Levin M, Babiker AG, Gibb DM. Mortality after fluid bolus in African children with severe infection. N Engl J Med. 2011 Jun 30;364(26):2483–95. doi: 10.1056/NEJMoa1101549. [DOI] [PubMed] [Google Scholar]
- 27.Onyango FE, Steinhoff MC, Wafula EM, Wariua S, Musia J, Kitonyi J. Hypoxaemia in young Kenyan children with acute lower respiratory infection. BMJ. 1993 Mar 6;306(6878):612–5. doi: 10.1136/bmj.306.6878.612. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Thilo EH, Park-Moore B, Berman ER, Carson BS. Oxygen saturation by pulse oximetry in healthy infants at an altitude of 1610 m (5280 ft). What is normal? Am J Dis Child. 1991 Oct;145(10):1137–40. doi: 10.1001/archpedi.1991.02160100069025. [DOI] [PubMed] [Google Scholar]
- 29.Shann F, Barker J, Poore P. Chloramphenicol alone versus chloramphenicol plus penicillin for severe pneumonia in children. Lancet. 1985 Sep 28;2(8457):684–6. doi: 10.1016/s0140-6736(85)92928-9. [DOI] [PubMed] [Google Scholar]
- 30.Straus WL, Qazi SA, Kundi Z, Nomani NK, Schwartz B. Antimicrobial resistance and clinical effectiveness of co-trimoxazole versus amoxycillin for pneumonia among children in Pakistan: randomised controlled trial. Pakistan Co-trimoxazole Study Group. Lancet. 1998 Jul 25;352(9124):270–4. doi: 10.1016/s0140-6736(97)10294-x. [DOI] [PubMed] [Google Scholar]
- 31.Duke T, Poka H, Dale F, Michael A, Mgone J, Wal T. Chloramphenicol versus benzylpenicillin and gentamicin for the treatment of severe pneumonia in children in Papua New Guinea: a randomised trial. Lancet. 2002 Feb 9;359(9305):474–80. doi: 10.1016/S0140-6736(02)07677-8. [DOI] [PubMed] [Google Scholar]
- 32.Addo-Yobo E, Anh DD, El-Sayed HF, Fox LM, Fox MP, Macleod W, Saha S, Tuan TA, Thea DM, Qazi S. Outpatient treatment of children with severe pneumonia with oral amoxicillin in four countries: the MASS study. Trop Med Int Health. May 4; doi: 10.1111/j.1365-3156.2011.02787.x. [DOI] [PMC free article] [PubMed] [Google Scholar]